SARS CoV-2 Spike Glycoprotein South Africa variant Positive Control for STJ506303 peptide (South Africa variant) (STJ506307)

SKU:
STJ506307-5

Shipping:
Free Shipping
Current Stock:
Applications: WB
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: SARS CoV-2 Spike Glycoprotein South Africa variant Positive Control for STJ506303 is synthetically produced from the 400-450 sequence about the South Africa variant and is suitable for use in western blot applications.
Formulation: Provided as 100 uL ready-to-use, in SDS-PAGE sample buffer (Laemelli's buffer) containing Tris, pH 6.8, 1 % SDS, Glycerol and Bromophenolblue blue as tracking dye. The sample is reduced by adding 2% beta mercaptoethanol. The protein concentration is
Storage Instruction: Store at-20°C for long term storage. Avoid freeze-thaw cycles.
Immunogen Region: 400-450
Specificity: This is positive control is recommended for use in combination with SARS CoV-2 Spike Glycoprotein South Africa variant antibody STJ506303.
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance